Literature DB >> 25857773

IMP-GMP specific cytosolic 5'-nucleotidase regulates nucleotide pool and prodrug metabolism.

Federico Cividini1, Daniela Nicole Filoni2, Rossana Pesi1, Simone Allegrini3, Marcella Camici1, Maria Grazia Tozzi1.   

Abstract

BACKGROUND: Type II cytosolic 5'-nucleotidase (cN-II) catalyzes the hydrolysis of purine and, to some extent, of pyrimidine monophosphates. Recently, a number of papers demonstrated the involvement of cN-II in the mechanisms of resistance to antitumor drugs such as cytarabine, gemcitabine and fludarabine. Furthermore, cN-II is involved in drug resistance in patients affected by hematological malignancies influencing the clinical outcome. Although the implication of cN-II expression and/or activity appears to be correlated with drug resistance and poor prognosis, the molecular mechanism by which cN-II mediates drug resistance is still unknown.
METHODS: HEK 293 cells carrying an expression vector coding for cN-II linked to green fluorescent protein (GFP) and a control vector without cN-II were utilized. A highly sensitive capillary electrophoresis method was applied for nucleotide pool determination and cytotoxicity exerted by drugs was determined with 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay.
RESULTS: Over-expression of cN-II causes a drop of nucleoside triphosphate concentration and a general disturbance of nucleotide pool. Over-expressing cells were resistant to fludarabine, gemcitabine and cytarabine independently of cN-II ability to hydrolyze their monophosphates.
CONCLUSIONS: An increase of cN-II expression is sufficient to cause both a general disturbance of nucleotide pool and an increase of half maximal inhibitory concentration (IC50) of the drugs. Since the monophosphates of cytarabine and gemcitabine are not substrates of cN-II, the protection observed cannot be directly ascribed to drug inactivation. GENERAL SIGNIFICANCE: Our results indicate that cN-II exerts a relevant role in nucleotide and drug metabolism through not only enzyme activity but also a mechanism involving a protein-protein interaction, thus playing a general regulatory role in cell survival. SENTENCE: Resistance to fludarabine, gemcitabine and cytarabine can be determined by an increase of cN-II both through dephosphorylation of active drugs and perturbation of nucleotide pool.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Cytarabine; Fludarabine; Gemcitabine; Resistance; cN-II

Mesh:

Substances:

Year:  2015        PMID: 25857773     DOI: 10.1016/j.bbagen.2015.03.017

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  The 4-N-acyl and 4-N-alkyl gemcitabine analogues with silicon-fluoride-acceptor: Application to 18F-Radiolabeling.

Authors:  Cesar Gonzalez; Andersson Sanchez; Jeffrey Collins; Ksenia Lisova; Jason T Lee; R Michael van Dam; M Alejandro Barbieri; Cheppail Ramachandran; Stanislaw F Wnuk
Journal:  Eur J Med Chem       Date:  2018-02-12       Impact factor: 6.514

2.  Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.

Authors:  Zhongyi Guo; Feng Wang; Yang Di; Lie Yao; Xinzhe Yu; Deliang Fu; Ji Li; Chen Jin
Journal:  Int J Nanomedicine       Date:  2018-08-29

3.  Cytosolic 5'-Nucleotidase II Is a Sensor of Energy Charge and Oxidative Stress: A Possible Function as Metabolic Regulator.

Authors:  Rossana Pesi; Simone Allegrini; Francesco Balestri; Mercedes Garcia-Gil; Federico Cividini; Laura Colombaioni; Lars Petter Jordheim; Marcella Camici; Maria Grazia Tozzi
Journal:  Cells       Date:  2021-01-18       Impact factor: 6.600

Review 4.  Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism.

Authors:  Nikolaos Tsesmetzis; Cynthia B J Paulin; Sean G Rudd; Nikolas Herold
Journal:  Cancers (Basel)       Date:  2018-07-23       Impact factor: 6.639

5.  The cytosolic 5'-nucleotidase cN-II lowers the adaptability to glucose deprivation in human breast cancer cells.

Authors:  Gabriel Bricard; Octavia Cadassou; Laure-Estelle Cassagnes; Emeline Cros-Perrial; Léa Payen-Gay; Jean-Yves Puy; Isabelle Lefebvre-Tournier; Maria Grazia Tozzi; Charles Dumontet; Lars Petter Jordheim
Journal:  Oncotarget       Date:  2017-06-27

Review 6.  Emerging Role of Purine Metabolizing Enzymes in Brain Function and Tumors.

Authors:  Mercedes Garcia-Gil; Marcella Camici; Simone Allegrini; Rossana Pesi; Edoardo Petrotto; Maria Grazia Tozzi
Journal:  Int J Mol Sci       Date:  2018-11-14       Impact factor: 5.923

7.  Cytosolic 5'-Nucleotidase II Silencing in a Human Lung Carcinoma Cell Line Opposes Cancer Phenotype with a Concomitant Increase in p53 Phosphorylation.

Authors:  Rossana Pesi; Edoardo Petrotto; Laura Colombaioni; Simone Allegrini; Mercedes Garcia-Gil; Marcella Camici; Lars Petter Jordheim; Maria Grazia Tozzi
Journal:  Int J Mol Sci       Date:  2018-07-20       Impact factor: 5.923

Review 8.  Purine-Metabolising Enzymes and Apoptosis in Cancer.

Authors:  Marcella Camici; Mercedes Garcia-Gil; Rossana Pesi; Simone Allegrini; Maria Grazia Tozzi
Journal:  Cancers (Basel)       Date:  2019-09-12       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.